Literature DB >> 14659433

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.

E Schleyer1, S Pursche, C H Köhne, U Schuler, U Renner, H Gschaidmeier, J Freiberg-Richter, T Leopold, A Jenke, M Bonin, T Bergemann, P le Coutre, M Gruner, M Bornhäuser, O G Ottmann, G Ehninger.   

Abstract

An isocratic online-enrichment HPLC-assay was developed allowing for the simple and fast separation and quantitation of STI-571 and its main metabolite N-desmethyl-STI (N-DesM-STI) in plasma, urine, cerebrospinal fluid (CSF), culture media and cell preparations in various concentrations using UV-detection at 260 nm. The analytical procedure consists of an online concentration of STI-571 and N-DesM-STI in the HPLC system followed by the elution on a ZirChrom-PBD analytical column. Time of analysis is 40 min including the enrichment time of 5 min. The detection limit is 10 ng/ml in plasma, CSF, culture medium (RPMI) and 25 ng/ml in urine for both STI-571 and N-DesM-STI. The intra-day precision, as expressed by the coefficient of variation (CV), in plasma samples ranges between 1.74 and 8.60% for STI-571 and 1.45 and 8.87% for N-DesM-STI. The corresponding values for urine measurements are 2.17-7.54% (STI-571) and 1.31-9.51% (N-DesM-STI). The inter-day precision analyzed over a 7-month time period was 8.31% (STI-571) or 6.88% (N-DesM-STI) and 16.45% (STI-571) or 14.83% (N-DesM-STI) for a concentration of 1000 ng/ml in plasma and 750 ng/ml in urine, respectively. Moreover, we demonstrate that with an alternative, but more time and labor consuming sample preparation and the implementation of electrochemical detection, a detection limit < 10 ng/ml can be achieved. The method described was used to perform pharmacokinetic measurements of STI-571 and N-desmethyl-STI in patient samples and for kinetic measurements of intracellular STI-571 and N-DesM-STI following in vitro incubation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14659433     DOI: 10.1016/j.jchromb.2003.10.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats.

Authors:  Josephine T Tauer; Lorenz C Hofbauer; Roland Jung; Sebastian Gerdes; Ingmar Glauche; Reinhold G Erben; Meinolf Suttorp
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

2.  Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Authors:  Stefan Pursche; Eberhard Schleyer; Malte von Bonin; Gerhard Ehninger; Samir Mustafa Said; Roland Prondzinsky; Thomas Illmer; Yanfeng Wang; Christian Hosius; Zariana Nikolova; Martin Bornhäuser; Gregor Dresemann
Journal:  Curr Clin Pharmacol       Date:  2008-09

3.  Monitoring imatinib plasma concentrations in chronic myeloid leukemia.

Authors:  Darlize Hübner Martins; Sandrine Comparsi Wagner; Tamyris Vianna Dos Santos; Lilian de Lima Feltraco Lizot; Marina Venzon Antunes; Marcelo Capra; Rafael Linden
Journal:  Rev Bras Hematol Hemoter       Date:  2011
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.